MyCancerHaven for Healthcare Professionals
My_Cancer_Haven provide a custom designed, curated and moderated, cloud based platform for cancer patients, and cancer focused experts, researchers and organizations to create cancer-type specific ecosystems to enable dissemination of information, educational and research initiatives, aiming to reduce disparity in cancer care and also offer tools for patients to form communities with their peers and a sanctuary with family and friends.
Ravi Vij & Dr. Dahlia Sano, MD discuss recent developments in Chronic Lymphocytic Leukemia (CLL)
Ravi Vij & Dr. Jeff Cherng, MD Discussing on Approaching The Front-line Treatment of DLBCL
Ravi Vij & Dr. Sameem Abedin, MD Discussing on CHIP, ICUS, CCUS, MDS and Vexas Syndrome
Ravi Vij & Dr. Geoffrey Shouse D.O, PhD, Discussing on Pirtobrutinib, A MyCancerHaven Podcast
Ravi Vij & Dr. Jeffery A. Zonder, MD Discussing on Smoldering Myeloma: To Treat or Not to Treat
Ravi Vij & Dr. Nina Wagner Johnston, MD Discuss Recent Advances in Treating Newly Diagnosed MCL
Ravi Vij & Dr. Dipenkumar Modi, MD, Discussing on CAR-T Cells for DLBCL as 2nd Line Therapy
Ravi Vij & Dr. Yi Lin, M.D, Ph.D, Discuss Setting Up an Outpatient Program for Cancer Immunotherapy
Ravi Vij & Dr. Amrita Krishnan, MD, Discussing on ASCO 2025: Novel Therapeutic Approaches
Ravi Vij & Dr. Hans Lee, MD., Discussing on Celmods in Multiple Myeloma
Ravi Vij & Dr. Samer AL Hadidi, MD Discusses on Four Drug Induction for Multiple Myeloma
Ravi Vij & Dr. Samir Parekh, MD Discusses on Targeting Protein Degradation Pathways in Myeloma
Ravi Vij & Dr. Attaya Suvannasankha on ASCO 2025: Bispecifics in Frontline MM Treatment
Ravi Vij & Dr. Krina Patel on ASCO 2025: BCMA CAR-T Cells in Multiple Myeloma and Amyloidosis
Ravi Vij & Dr. Gurbakhash Kaur MD on Anitocabtagene Autoleucel for Relapsed/Refractory Myeloma
Ravi Vij & Dr. Gurbakhash Kaur | Talquetamab in Relapsed/Refractory Multiple Myeloma Discussion
Ravi Vij & Dr. Sikander Ailawadhi MD, Discusses ASCO 2025: Subcutaneous Isatuximab At Last!
Ravi Vij & Dr. Jonathan L. Kaufman MD Discusses on ASCO 2025: Trispecifics For Multiple Myeloma
Ravi Vij & Dr. Ola Landgren on ASCO 2025: Advances in Dara-KRd Clinical Trial for Multiple Myeloma
Ravi Vij & Dr. Heather J Landau MD | Discusses on ASCO 2025: CAR-T NXC 201 For Amyloidis
Ravi Vij & Dr. Attaya Suvannasankha, MD Discusses About Use of MRD in Management of Multiple Myeloma
Ravi Vij and Dr. Brea Lipe MD, Discussing on ASCO 2025: MRD and Multiple Myeloma
Ravi Vij & Dr. Peter Voorhees, MD | ASCO 2025: Is CARTITUDE-1 Starting to Cure Multiple Myeloma?
Ravi Vij & Dr. Binod Dhakal, MD Discuss ASCO 2025 MIDAS Trial: Is This the Farewell to Transplant?
Ravi Vij & Dr. Nitin Jain Discuss AMPLIFY: Acalabrutinib + Venetoclax + Obinutuzumab in CLL
3B | A MyCancerHaven™ Expert Roundtable: Navigating Treatment in First Through Third Relapse
Ravi Vij, in discussion with Dr. Samuel Urrutia, MD on Low-Risk MDS: Updates from ASH 2024
Ravi Vij Discusses Recent Developments in Chronic Lymphocytic Leukemia (CLL) with Dr. Dahlia Sano MD
Ravi Vij discusses Arlocabtagene Autoleucel, a GPRC5D-targeted CAR T therapy, with Dr. Luciano Costa
Ravi Vij discusses Phase III trial of Ponatinib + Blinatumomab for Ph+ ALL with Dr. Anand Patel, MD